Systematic evaluation of Patient-Reported Outcome protocol content and reporting in cancer trials.

Kyte, Derek and Retzer, Ameeta and Ahmed, Khaled and Keeley, Thomas and Armes, Jo and Brown, Julia M and Calman, Lynn and Gavin, Anna and Glaser, Adam W and Greenfield, Diana M and Lanceley, Anne and Taylor, Rachel M and Velikova, Galina and Brundage, Michael and Efficace, Fabio and Mercieca-Bebber, Rebecca and King, Madeleine T and Turner, Grace and Calvert, Melanie (2019) Systematic evaluation of Patient-Reported Outcome protocol content and reporting in cancer trials. Journal of the National Cancer Institute. ISSN 1460-2105.

Full text not available from this repository.
Official URL: https://academic.oup.com/jnci/advance-article/doi/...

Abstract

BACKGROUND

Patient-Reported Outcomes (PROs) are captured within cancer trials to help future patients and their clinicians make more informed treatment decisions. However, variability in standards of PRO trial design and reporting threaten the validity of these endpoints for application in clinical practice.

METHODS

We systematically investigated a cohort of randomized controlled cancer trials which included a primary or secondary PRO. For each trial, an evaluation of protocol and reporting quality was undertaken using standard checklists. General patterns of reporting where also explored.

RESULTS

Protocols (101 sourced, 44.3%) included a mean of 10/33 (range = 2-19, SD = 4) PRO protocol checklist items. Recommended items frequently omitted included: the rationale and objectives underpinning PRO collection and approaches to minimise/address missing PRO data. Of 160 trials with published results, 61 (38.1%, 95% CI = 30.6% to 45.7%) failed to include their PRO findings in any publication (mean 6.43-year follow-up); these trials included 49,568 participants. Although two-thirds of included trials published PRO findings, reporting standards were often inadequate according to international guidelines (mean inclusion of 3/14 (range = 0-11, SD = 3) CONSORT PRO Extension checklist items). Over half of trials publishing PRO results in a secondary publication (12/22, 54.5%) took 4 or more years to do so following trial closure, with 8 (36.4%) taking 5-8 years and one trial publishing after 14 years.

CONCLUSIONS

PRO protocol content is frequently inadequate, and non-reporting of PRO findings is widespread, meaning patient-important information may not be available to benefit patients, clinicians and regulators. Even where PRO data are published, there is often considerable delay and reporting quality is suboptimal. This study presents key recommendations to enhance the likelihood of successful delivery of PROs in the future.

Item Type: Article
Subjects: QZ Pathology. Oncology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 16 Apr 2019 10:07
Last Modified: 16 Apr 2019 10:07
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/2035

Actions (login required)

View Item View Item